We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Katelyn A. Staub-Zamperini
Katelyn A. Staub-Zamperini
Products
PRODUCTS
Philips Respironics, Inc.
Katelyn A. Staub-Zamperini
Price:
$117.00
View
Dymax Corp.
Katelyn A. Staub-Zamperini
Price:
$117.00
View
Blue Belt Technologies
Katelyn A. Staub-Zamperini
Price:
$117.00
View
Rinovum Women's Health
Katelyn A. Staub-Zamperini
Price:
$117.00
View
Oberg Medical Products Co.
Katelyn A. Staub-Zamperini
Price:
$117.00
View
Cadence Device Assembly, Inc.
Katelyn A. Staub-Zamperini
Price:
$117.00
View
AcousticSheep, LLC
Katelyn A. Staub-Zamperini
Price:
$117.00
View
American Contract Systems
Katelyn A. Staub-Zamperini
Price:
$117.00
View
American Dental Sleep Medicine IP LLC
Katelyn A. Staub-Zamperini
Price:
$117.00
View
Invacare Corp.
Christina L. Bigham
,
Laureen M. Geniusz
,
John E. Marszalek
, and
Katelyn A. Staub-Zamperini
Price:
$117.00
View
View All Products by Katelyn A. Staub-Zamperini
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
FDA, FTC and DOJ Enforcement of Medical Device Regulations
Using Real-World Evidence in Drug and Device Submissions
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More